Trial Profile
Study to evaluate the risk of Herpes Zoster associated with delayed-release dimethyl fumarate treatment in patients with Relapsing/Remitting Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Oct 2018
Price :
$35
*
At a glance
- Drugs Dimethyl fumarate (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 30 Oct 2018 New trial record
- 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis